Fighting for the drug that pauses cystic fibrosis

Cystic Fibrosis is a life-reducing genetic lung disorder and while outcomes have improved, half of those with it do not live beyond 40.

Orkambi is a drug that targets a mutation that around 50% of people with cystic fibrosis in the UK have. It has been shown to improve lung health by up to 42%.

Licensed for use in the UK since 2015, it costs around £105,000 per patient per year so is not available on the NHS, except for certain people on compassionate grounds.


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials

Forgot your details?